Clene to Present at the Emerging Growth Conference

Rhea-AI Summary

Clene (Nasdaq: CLNN) will present a corporate update at the Emerging Growth Conference on October 23, 2025 at 3:10 p.m. ET. The company and its subsidiary Clene Nanomedicine, a clinical-stage biopharmaceutical focused on mitochondrial health and treatments for neurodegenerative diseases including ALS and MS, will deliver the virtual presentation.

A live webcast and accompanying slides will be available via the Events section of Clene's website and by registration at the provided webcast link. A replay will be posted on the conference portal and the Emerging Growth YouTube channel after the event.

SALT LAKE CITY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.

Virtual Presentation Details
Date: October 23, 2025
Time of Presentation: 3:10 p.m. ET
Format: Corporate update

A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register for and view the webcast, along with accompanying slides, here: https://goto.webcasts.com/starthere.jsp?ei=1717092&tp_key=1ddfafa563&sti=clnn. A replay of the presentation will also be available through the conference portal and the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference, following the event.

About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856

FAQ

When will Clene (CLNN) present at the Emerging Growth Conference?

Clene will present on October 23, 2025 at 3:10 p.m. ET.

How can investors watch the Clene (CLNN) Emerging Growth Conference presentation?

Watch live via the webcast link provided by registration or on Clene's Events webpage; slides are available with the webcast.

Will a replay of the Clene (CLNN) presentation be available after October 23, 2025?

Yes. A replay will be posted on the conference portal and the Emerging Growth YouTube channel after the event.

What topics will Clene (CLNN) cover in the October 23, 2025 presentation?

The presentation is described as a corporate update and will cover recent company developments and strategy.

What is Clene Nanomedicine's clinical focus mentioned in the presentation notice?

Clene Nanomedicine is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases including ALS and MS.